WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience MBF Bioscience Autoneuron
 QUICK SEARCH:   [advanced]


     
-


HOME
  |  
SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, November 8, 2006, 26(45):11652-11664; doi:10.1523/JNEUROSCI.2490-06.2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Franciosi, S.
Right arrow Articles by McLarnon, J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Franciosi, S.
Right arrow Articles by McLarnon, J. G.

 Previous Article  |  Next Article 

Neurobiology of Disease
Broad-Spectrum Effects of 4-Aminopyridine to Modulate Amyloid beta1–42-Induced Cell Signaling and Functional Responses in Human Microglia

Sonia Franciosi,1 Jae K. Ryu,1 Hyun B. Choi,1,2 Lesley Radov,4 Seung U. Kim,2,3 and James G. McLarnon1

1Departments of Anesthesiology, Pharmacology, and Therapeutics and 2Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z3, 3Brain Disease Research Center, Ajou University, Suwon 443-749, Korea, and 4Astra Zeneca CNS Discovery, Wilmington, Delaware 19850

Correspondence should be addressed to Dr. James G. McLarnon, Departments of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Vancouver, British Columbia, Canada V6T 1Z3. Email: mclarnon{at}interchange.ubc.ca

We investigated the modulating actions of the nonselective K+ channel blocker 4-aminopyridine (4-AP) on amyloid beta (Abeta1–42)-induced human microglial signaling pathways and functional processes. Whole-cell patch-clamp studies showed acute application of Abeta1–42 (5 µM) to human microglia led to rapid expression of a 4-AP-sensitive, non-inactivating outwardly rectifying K+ current (IK). Intracellular application of the nonhydrolyzable analog of GTP, GTP{gamma}S, induced an outward K+ current with similar properties to the Abeta1–42-induced IK including sensitivity to 4-AP (IC50 = 5 mM). Reverse transcriptase-PCR showed a rapid expression of a delayed rectifier Kv3.1 channel in Abeta1–42-treated microglia. Abeta1–42 peptide also caused a slow, progressive increase in levels of [Ca2+]i (intracellular calcium) that was partially blocked by 4-AP. Chronic exposure of human microglia to Abeta1–42 led to enhanced p38 mitogen-activated protein kinase and nuclear factor {kappa}B expression with factors inhibited by 4-AP. Abeta1–42 also induced the expression and production of the pro-inflammatory cytokines interleukin (IL)-1beta, IL-6, and tumor necrosis factor-{alpha}, the chemokine IL-8, and the enzyme cyclooxygenase-2; 4-AP was effective in reducing all of these pro-inflammatory mediators. Additionally, toxicity of supernatant from Abeta1–42-treated microglia on cultured rat hippocampal neurons was reduced if 4-AP was included with peptide. In vivo, injection of Abeta1–42 into rat hippocampus induced neuronal damage and increased microglial activation. Daily administration of 1 mg/kg 4-AP was found to suppress microglial activation and exhibited neuroprotection. The overall results suggest that 4-AP modulation of an Abeta1–42-induced IK (candidate channel Kv3.1) and intracellular signaling pathways in human microglia could serve as a therapeutic strategy for neuroprotection in Alzheimer's disease pathology.

Key words: Alzheimer's disease; amyloid beta peptide; 4-aminopyridine; microglia; inflammation; cytokines


Received June 13, 2006; revised Sept. 21, 2006; accepted Sept. 27, 2006.

Correspondence should be addressed to Dr. James G. McLarnon, Departments of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Vancouver, British Columbia, Canada V6T 1Z3. Email: mclarnon{at}interchange.ubc.ca






-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help

-
Copyright 2008 by Society for Neuroscience ONLINE ISSN: 1529-2401
-